The Globe and Mail reports in its Wednesday edition that Raymond James analyst Michael Freeman started coverage on Well Health Technologies with an "outperform" ranking and $8.50 share target. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $7.96. Mr. Freeman says in a note: "In our view, Well Health Technologies has become the centre of gravity in Canada's primary healthcare and digital health ecosystem, and is a rapidly ascendant power in U.S. hybrid care, growing by way of disciplined, accretive M&A -- approximately 50 acquisitions executed since inception -- and strong organic growth, posting 19 per cent year-over-year in FY22. And, while Well Health's U.S. presence is a newer part of its story, it's no less important: Well Health drove nearly 60 per cent of its FY22 total Rev. from its U.S. businesses in primary, specialty, and virtual care. ... Well Health leverages its large, growing footprint of physical clinics, combined with its increasingly broad and interconnected suite of digital tools to empower healthcare practitioners and patients, looking to improve health outcomes and yield efficiencies in overstressed healthcare markets."